Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors


This is a multicenter, open-label, Phase 1a/1b study of orally administered LOXO-101 in adult subjects with advanced solid tumors that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists.

Study Start Date

April 2014

Estimated Completion Date

January 2017


  • Drug: LOXO-101


  • Oncology: Pharmacology/Therapy
  • Physician Assistant: Hematology/Oncology

MeSH Terms

  • Adult Solid Tumor
  • LOXO-101
  • Neoplasms

Study ID

Loxo Oncology, Inc. -- LOXO-TRK-14001



Trial ID


Study Type


Trial Phase

Phase 1

Enrollment Quota



Loxo Oncology, Inc.

Phase 1a [Inclusion]
  • Locally advanced or metastatic adult solid tumor that has progressed or was nonresponsive to available therapies and for which no standard or available curative therapy exists
  • ECOG score of 0 or 1
  • Adequate hematologic, hepatic, and renal function
  • Phase 1a [Exclusion] • Prior exposure to a selective TRK-blocking agent Phase 1b [Inclusion]
  • Phase 1a inclusion criteria
  • Tumor that is positive for TRK alteration Phase 1b [Exclusion] • Phase 1a exclusion criteria
  • Gender



    18 Years and older

    Accepts Healthy Volunteers


    Study Locations and Contact Information (7)

    Study Location Distance Name Phone Email
    University Hospitals Case Medical Center - Cleveland, Ohio 48.3 miles None None None
    University of Pennsylvania - Philadelphia, Pennsylvania 134.5 miles None None None
    Massachusetts General Hospital - Boston, Massachusetts 137.9 miles None None None
    SCRI - Nashville, Tennessee 810.5 miles None None None
    MD Anderson Cancer Center - Houston, Texas 1,475.7 miles None None None
    University of Colorado Cancer Center - Aurora, Colorado 1,658.2 miles None None None
    OHSU - Portland, Oregon 2,468.2 miles None None None

    ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.